Cargando…

Drug induced rhabdomyolysis

Rhabdomyolysis is a clinical condition of potential life threatening destruction of skeletal muscle caused by diverse mechanisms including drugs and toxins. Given the fact that structurally not related compounds cause an identical phenotype pinpoints to common targets or pathways, responsible for ex...

Descripción completa

Detalles Bibliográficos
Autor principal: Hohenegger, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science Ltd 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3387368/
https://www.ncbi.nlm.nih.gov/pubmed/22560920
http://dx.doi.org/10.1016/j.coph.2012.04.002
_version_ 1782237092657496064
author Hohenegger, Martin
author_facet Hohenegger, Martin
author_sort Hohenegger, Martin
collection PubMed
description Rhabdomyolysis is a clinical condition of potential life threatening destruction of skeletal muscle caused by diverse mechanisms including drugs and toxins. Given the fact that structurally not related compounds cause an identical phenotype pinpoints to common targets or pathways, responsible for executing rhabdomyolysis. A drop in myoplasmic ATP paralleled with sustained elevations in cytosolic Ca(2+) concentration represents a common signature of rhabdomyolysis. Interestingly, cardiac tissue is hardly affected or only secondary, as a consequence of imbalance in electrolytes or acid–base equilibrium. This dogma is now impaired by compounds, which show up with combined toxicity in heart and skeletal muscle. In this review, cases of rhabdomyolysis with novel recently approved drugs will be explored for new target mechanisms in the light of previously described pathomechanisms.
format Online
Article
Text
id pubmed-3387368
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Elsevier Science Ltd
record_format MEDLINE/PubMed
spelling pubmed-33873682012-07-05 Drug induced rhabdomyolysis Hohenegger, Martin Curr Opin Pharmacol Article Rhabdomyolysis is a clinical condition of potential life threatening destruction of skeletal muscle caused by diverse mechanisms including drugs and toxins. Given the fact that structurally not related compounds cause an identical phenotype pinpoints to common targets or pathways, responsible for executing rhabdomyolysis. A drop in myoplasmic ATP paralleled with sustained elevations in cytosolic Ca(2+) concentration represents a common signature of rhabdomyolysis. Interestingly, cardiac tissue is hardly affected or only secondary, as a consequence of imbalance in electrolytes or acid–base equilibrium. This dogma is now impaired by compounds, which show up with combined toxicity in heart and skeletal muscle. In this review, cases of rhabdomyolysis with novel recently approved drugs will be explored for new target mechanisms in the light of previously described pathomechanisms. Elsevier Science Ltd 2012-06 /pmc/articles/PMC3387368/ /pubmed/22560920 http://dx.doi.org/10.1016/j.coph.2012.04.002 Text en © 2012 Elsevier Ltd. https://creativecommons.org/licenses/by-nc-nd/3.0/ Open Access under CC BY-NC-ND 3.0 (https://creativecommons.org/licenses/by-nc-nd/3.0/) license
spellingShingle Article
Hohenegger, Martin
Drug induced rhabdomyolysis
title Drug induced rhabdomyolysis
title_full Drug induced rhabdomyolysis
title_fullStr Drug induced rhabdomyolysis
title_full_unstemmed Drug induced rhabdomyolysis
title_short Drug induced rhabdomyolysis
title_sort drug induced rhabdomyolysis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3387368/
https://www.ncbi.nlm.nih.gov/pubmed/22560920
http://dx.doi.org/10.1016/j.coph.2012.04.002
work_keys_str_mv AT hoheneggermartin druginducedrhabdomyolysis